A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People "APOLLO"


Phase 3 Results

Summary of Purpose

This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood pressure (SBP) 130 to 159 mmHg, in preventing major cardiovascular (CV) events and on global... Trial Stopped: Terminated early in agreement with Health Authorities for feasibility reasons

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 27 February 2014.

1 Jan 2011 10 Dec 2010 1 Nov 2012 1 Nov 2012 1 Feb 2014 18 Dec 2013
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Factorial Assignment


  • Novartis Pharmaceuticals